Option chain shows key data for NuCana's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NuCana.

NuCana (NASDAQ:NCNA) Stock, Option Chain

NuCana

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Portland,,Or,,Usa,-,Mar,12,,2020:,Dow,Jones,Index

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CERO

GNLN

JZXN

NCNA

XELB

Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook

movers image

Pre-Market Outlook

Movers

AMLI

ATCH

CNTM

CNXC

GSX Techedu Inc. American Depositary Shares

GOTU

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

Kintara Therapeutics, Inc. - Common Stock

KTRA

MDXH

NLSP

SEEL

SONN

SONO

TBIO

VSME

Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket

Crude Oil 6- logo

ASND

ITOS

NUVL

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

NuCana PLC

Press Releases

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

Health Care

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

General

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Legal

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aditxt

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

Genprex

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

SILO Pharma

Synaptogenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Oppenheimer

Truist Securities

Jefferies

Comments

NuCana

NuCana (NCNA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell